New hope for aggressive prostate cancer: carboplatin combo tested in phase 3 trial

NCT ID NCT07591467

Not yet recruiting Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding carboplatin to standard therapy can delay cancer growth in men with aggressive prostate cancer that has spread and has either a BRCA gene mutation or neuroendocrine features. About 330 participants will receive either standard care alone or standard care plus carboplatin. The goal is to see if the combination keeps the cancer from progressing longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA-MUTATED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA-MUTATED NEUROENDOCRINE-DIFFERENTIATED AGGRESSIVE METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CLCC Paoli-Calmettes

Marseille, 13009, France
CLCC-ICL

Nancy, 54519, France
CLCC-Léon Bérard

Lyon, 69008, France
Gustave Roussy

Villejuif, 94805, France
Hôpital Saint André

Bordeaux, 33075, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.